Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2005
08/16/2005US6929930 Nucleotide sequences coding antigenic peptide for use in diagnosis of bacterial infections
08/16/2005US6929913 Compositions and methods for regulating autolytic processes in bacteria
08/16/2005US6929910 Diagnostic and therapeutic methods using the H37 tumor suppressor gene
08/16/2005US6929818 Methods and clinical devices for the inhibition or prevention of mammalian cell growth
08/16/2005US6929806 Agents for improving lipid metabolism and reducing high blood pressure
08/16/2005US6929796 Methods to treat undesirable immune responses
08/16/2005US6929794 IL-12 as an adjuvant for Bordetella pertussis vaccines
08/16/2005US6929793 Nutritional composition for treating an immune condition
08/16/2005US6929791 An antibody which binds to an interleukin-2 (IL-2) peptide of given amino acid sequence; vectors
08/16/2005US6929012 Process for the isolation of a major harmful oxidant from cigarette smoke
08/16/2005CA2342974C Methods and compositions for inhibition of angiogenesis
08/16/2005CA2236164C Pulmonary surfactant peptide solubilization process
08/16/2005CA2157500C Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
08/16/2005CA2084075C The ciliary neurotrophic factor receptor
08/16/2005CA2078221C Pharmaceutical compositions comprising taurolidine and/or taurultam
08/11/2005WO2005073383A2 HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY
08/11/2005WO2005073378A1 MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
08/11/2005WO2005073374A1 Novel tumor antigen protein and utilization of the same
08/11/2005WO2005073367A1 Production and purification of recombinant arylsulfatase a
08/11/2005WO2005073250A2 Medical treatment using an rna1 targeting a human notch signalling pathway member
08/11/2005WO2005073249A1 Corticotropin-releasing factor receptor 1 (crfr1) agonist polypeptides
08/11/2005WO2005073247A1 Amino acid and peptide conjugates of amiloride and methods of use thereof
08/11/2005WO2005072893A1 Functionalized colloidal metal compositions and methods
08/11/2005WO2005072777A2 Conjugates of amyloid proteins as vaccines for amyloid-related diseases
08/11/2005WO2005072771A1 Neuroprotective complex for treatment of cerebral ischemia and injury
08/11/2005WO2005072770A1 Treatment of bone metastases by means of pth receptor agonists
08/11/2005WO2005072769A1 Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
08/11/2005WO2005072768A1 Preventive and/or remedy for retinopathy
08/11/2005WO2005072767A1 Agent for improving sugar metaboic function
08/11/2005WO2005072766A2 Peptides that bind to hsp90 proteins
08/11/2005WO2005072765A2 An efficient method to synthesize benzyl group-protected alpha-pentagalloylglucose (α-pgg) and its analogues
08/11/2005WO2005072764A2 Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
08/11/2005WO2005072700A2 Haemostatic sprays and compositions
08/11/2005WO2005072419A2 Gastrointestinal proliferative factor and uses thereof
08/11/2005WO2005072417A2 Vascular endothelial growth factors and methods of their use
08/11/2005WO2005072380A2 Membrane attack complexes associated with circulating immune complexes
08/11/2005WO2005072347A2 Inositol 1,4,5- trisphosphate receptor mutants and uses thereof
08/11/2005WO2005072295A2 Methods for reducing oxidative damage
08/11/2005WO2005072277A2 Amidated parathyroid hormone fragments and uses thereof
08/11/2005WO2005072270A2 Methods and compositons for treating cancer
08/11/2005WO2005072261A2 Lactoferrin-treated filament materials
08/11/2005WO2005072241A2 Inhibition of bright function as a treatment for excessive immunoglobulin production
08/11/2005WO2005072141A2 Peptide inhibitors of rhoa signaling
08/11/2005WO2005072139A2 Use of aerosolized antithrombin to treat acute lung injury
08/11/2005WO2005072126A2 Antibodies for inhibiting blood coagulation and methods of use thereof
08/11/2005WO2005072076A2 Novel nucleic acids and polypeptides
08/11/2005WO2005072045A2 The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
08/11/2005WO2005066204A3 Neutralizing epitope-based growth enhancing vaccine
08/11/2005WO2005060990A3 Use of il-6 in the preparation of pharmaceutical compositions for treating and preventing liver injury
08/11/2005WO2005056551A3 Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments
08/11/2005WO2005056046A3 Methods for treating inflammation using thyroid stimulating hormone
08/11/2005WO2005055973A3 Endoparasiticidal agents for topical application
08/11/2005WO2005053617A3 Compositions and methods comprising collagen
08/11/2005WO2005044854A3 Antagonist anti-cd40 monoclonal antibodies and methods for their use
08/11/2005WO2005042565A3 Cyclin groove inhibitors
08/11/2005WO2005041877A9 Method of inhibiting rejection following organ transplantation
08/11/2005WO2005040375A9 A fungal immuromodulatory protein produced by microorganisme and uses thereof
08/11/2005WO2005034856A3 Targeted drug-formaldehyde conjugates and methods of making and using the same
08/11/2005WO2005030804A3 A method of modulating cell survival, differentiation and/or synaptic plasticity
08/11/2005WO2005025514A3 Compounds that modulate neuronal growth and their uses
08/11/2005WO2005021580A3 Hydrogels for modulating cell migration and matrix deposition
08/11/2005WO2005019457A3 NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
08/11/2005WO2005013800A3 Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity
08/11/2005WO2005000877A3 Novel melanocortin receptor templates, peptides, and use thereof
08/11/2005WO2005000283A3 A method of treating degenerative disc disease
08/11/2005WO2004103312A3 Peptides useful as hiv fusion inhibitors
08/11/2005WO2004101607A3 Comparative ligand mapping from mhc class i positive cells
08/11/2005WO2004099376A3 Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity
08/11/2005WO2004094463A3 Peptide inhibitors of autophosphorylation protein kinases
08/11/2005WO2004083396A3 Methods for the identification of inhibitors of porphobilinogen deaminase, bifunctional purine biosynthetic protein, and a transcription factor as antibiotics
08/11/2005WO2004070025A3 Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
08/11/2005WO2004060309A3 Methods of treating and/or preventing autoimmune diseases
08/11/2005WO2004056849A3 Methanobactin: a copper binding compound having antibiotic and antioxidant activity isolated from methanotrophic bacteria
08/11/2005WO2004042063A8 Pharmaceutical composition for preparing a medicine for treating and/or preventing a pathology related to an obsessive behaviour or obesity
08/11/2005WO2004039940A3 Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
08/11/2005WO2004030522A3 Diagnosis and monitoring of diseases
08/11/2005WO2004028457A3 PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
08/11/2005WO2004013283A3 Thioredoxin mutants and uses thereof
08/11/2005WO2004007667A3 Polynucleotide and polypeptide fat metabolism regulators and uses thereof
08/11/2005WO2004004662A3 Compositions and methods for the diagnosis and treatment of tumor
08/11/2005WO2003087762A3 Methyl-cpg binding domain protein 2 homologs
08/11/2005WO2003077836A3 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
08/11/2005WO2003076634A3 Transcriptional regulation of ptp-1b
08/11/2005WO2003023000A3 Linear dna fragments for gene expression
08/11/2005US20050177888 Useful for selecting compounds that inhibit beta secretase for treatment of neurodegenerative diseases, such as Alzheimer's disease.
08/11/2005US20050177886 T1R3 transgenic animals, cells and related methods
08/11/2005US20050177225 Coating a central venous catheter with an antifibrotic agent, such as a cell cycle inhibitor, and an optional antibiotic
08/11/2005US20050177118 Inplantable device; wound healing agents for bones, soft tissure; polyelectrolyte complex; three-dimensional polymer network
08/11/2005US20050177103 Implantable catheter for lumen of a blood vessel; a stent, stent graft, covered stent, aneurysm coil, embolic agent, drug delivery catheter or balloon; drug coated or impregnated; adhesion; self-expandable
08/11/2005US20050176993 Urokinase inhibitors, production and use thereof
08/11/2005US20050176944 Intracellular signaling polypeptide for identifying modulator for prevention and treatment cell proliferative, endocrine, autoimmune/inflammatory, neurological, gastrointestinal, reproductive, developmental, and vesicle trafficking disorders
08/11/2005US20050176931 Eotaxin : eosinophil chemotactic cytokine
08/11/2005US20050176930 Nucleotide sequences coding tumor associated antigen for use in diagnosis, prevention and treatment of cell proliferative disorders; mimetics; antitumor agents
08/11/2005US20050176927 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, agonists, and antagonists; drug screening; diagnosis
08/11/2005US20050176753 controlling signal transduction; anticancer agents; antitumor agnets; atherosclerosis; vision defects; antidiabetic agents; antiinflammatory agents
08/11/2005US20050176671 Drug screening; competitive binding; antitumor agents, antiproliferative agents, as promoter providing neuronal cell growth, wound healing, and cerebral injury healing; receptor binding assay, gene expression
08/11/2005US20050176669 Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence
08/11/2005US20050176666 Each double stranded siNA sequence is between 18 and 23 nucleotides, directs gene cleavage and also has a complementary antisense region; antiinflammatory agents; respiratory system disorders
08/11/2005US20050176664 RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
08/11/2005US20050176663 RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA)
1 ... 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 ... 3163